Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer MetastaticThe aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced NSCLC.
A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy
Lung NeoplasmsThoracic Neoplasms3 moreThe goal of this clinical research study is to test the use of a minimally invasive multimodality image-guided (MIMIG) intervention system used for performing a lung biopsy. The safety of the MIMIG intervention system will also be studied.
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel...
Squamous Non-Small Cell Lung CancerThe purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Cognitive Behavioral Therapy (CBT)-Insomnia for Lung Cancer
Chronic InsomniaThe purpose of this study is to determine whether cognitive behavioral therapy (CBT) is effective for insomnia in lung cancer survivors.
Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung...
CarcinomaNon-small Cell LungThioredoxin reductase plays an critical role in lung cancer patients, in vitro study showed that, ethaselen, specific inhibitor of thioredoxin reductase, could inhibit lung cancer cell growth and induce apoptosis. In China, phase 1 clinical trials of ethaselen showed that 1200 mg dose ethaselen could be well tolerated, in pre-clinical study we found that, approximately 50% non-small cell lung cancers harbored high thioredoxin reductase expression(IHC result ++ or +++), phase 1a/b of ethaselen had finished in 2008, the result showed that 1200mg ethaselen per day was safety and tolerated by Chinese malignant tumor patients.In pre-clinical research, our group found that, elevated of thioredoxin reductase activity was associated with the expression of thioredoxin reductase tested by immunohistochemistry, which means high expression of this enzyme may be a favourite predicted factor of ethaselen, the specific inhibitor of thioredoxin reductase.
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Adult RhabdomyosarcomaLung Metastases13 moreThis pilot clinical trial studies intensity-modulated radiation therapy (IMRT) in treating younger patients with lung metastases. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated...
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung CancerThis research study examines the use of Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) in patients with lung cancer. Abraxane is a chemotherapy approved to treat patients with breast cancer. Doctors want to know if Abraxane is safe and effective in treating patients with lung cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) and epidermal growth factor receptor (EGFR) mutations.
Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small...
Stage IA Non-small Cell Lung CancerStage IB Non-small Cell Lung Cancer3 moreThis research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer...
Non-Small Cell Lung CancerThis open-label, multi-center study will evaluate the progression-free survival and safety of erlotinib in participants with locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Participants will receive daily oral doses of erlotinib until disease progression or unacceptable toxicity.
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to...
Non-small Cell Lung CancerSquamous Cell CarcinomaThis randomized, multicenter,open-label phase II/III study is to evaluate the effects of chemotherapy combination with autologous cytokine-induced killer Cell immunotherapy in patients with stage IIIb-IV squamous non-small-cell lung cancer